A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2002
12/05/2002	WO2001019408A9 Nucleic acids encoding polyepitope polypeptides
12/05/2002	US20020183934 Methods for making character strings, polynucleotides and polypeptides having desired characteristics
12/05/2002	US20020183508 Sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
12/05/2002	US20020183500 Nucleotide sequence coding polypeptide for use in the treatment, diagnosis, classification and imaging of lung cancer
12/05/2002	US20020183484 Immunogenic formulation and process for preparation thereof
12/05/2002	US20020183385 Administering a therapeutically effective amount of arsenic compounds to a mammal for treating solid tumor
12/05/2002	US20020183271 Administering to the patient a human MDA-7 polypeptide or a nucleic acid expressing the human MDA-7 polypeptide in eukaryotic cells, whereby the MDA-7 polypeptide inhibits angiogenesis in the patient
12/05/2002	US20020183269 Novel compounds
12/05/2002	US20020183251 For use as vaccines, and other drugs for the diagnosis and therapy of prostate cancer
12/05/2002	US20020183250 For use in therapy of sleep disorders
12/05/2002	US20020182730 Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
12/05/2002	US20020182725 New antigen presenting cells, a process for preparing the same and their use as cellular vaccines
12/05/2002	US20020182706 Purification of viral envelope proteins; obtain cell, transfect with genetically engineered virus, lyse cell, recover envelope proteins
12/05/2002	US20020182685 In vivo generation of antibodies against antigens secreted in a host by transfected MEL cells
12/05/2002	US20020182683 Vascular endothelial growth factor 2
12/05/2002	US20020182676 Ob receptor and methods for the diagnosis and treatment of body weight disorders, including obesity and cachexia
12/05/2002	US20020182596 Compounds for immunodiagnosis of prostate cancer and methods for their use
12/05/2002	US20020182258 Microparticles for delivery of nucleic acid
12/05/2002	US20020182254 Biodegradable blend of polycaprolactone and crystallization modifier composed of a crystalline fatty acid or crystalline fatty acid ester of polyhydric alcohol for use in the controlled release of biologically active proteins
12/05/2002	US20020182231 Methods of stem cell manipulation for immunotherapy
12/05/2002	US20020182228 Methods for producing self-replicating infectious RSV particles comprising recombinant RSV genomes or antigenomes and the N, P, L, and M2 proteins
12/05/2002	US20020182226 For the prevention of Haemophilus Influenzae Type B (Hib) infections; especially multivalent vaccines
12/05/2002	US20020182224 Recombinant fusion protein comprising an amino acid sequence selected from the 27/28 kDa cercarial elastase sequence of S. mansoni fused to a protein selected from suitable bacterial, phage and viral proteins
12/05/2002	US20020182223 Eukaryotic double-stranded RNA expression vector comprising: (a) a designated DNA sequence of interest; and (b) a pair of promoters on opposite ends of the designated DNA oriented towards each other
12/05/2002	US20020182222 That have "evolved" due to gene shuffling in vitro for inclusion of "cross-clade" characteristics.
12/05/2002	US20020182221 Recombinant papillomavirus vaccine and method for production and treatment
12/05/2002	US20020182220 Isolating a heat shock protein 70- peptide complex from the mammal from tumor cells or cells infected with a virus, bacteria or infectious agent; and administering the heat shock protein peptide complex
12/05/2002	US20020182219 Cancer immunotherapy
12/05/2002	US20020182218 Therapeutic anti-melanoma compounds
12/05/2002	US20020182216 Eliciting a T-cell mediated immune response in an animal, comprising administering to the animal an extract of an egg comprising transfer factor generated by said source animal
12/05/2002	US20020182214 Tumor associated internalizing antigens and methods for targeting therapeutic agents
12/05/2002	US20020182213 Method for the treatment of fibrosis
12/05/2002	US20020182212 Compositions and methods for treating hyperimmune response in the eye
12/05/2002	US20020182211 Binds CD80 and/or CD86; an alanine at position +29 is substituted with tyrosine, leucine, tryptophan, or threonine, and a leucine at position +104 is substituted with a glutamic acid
12/05/2002	US20020182210 Treatment of central nervous system diseases by antibodies against glatiramer acetate
12/05/2002	US20020182208 Glycosylated antibody
12/05/2002	US20020182207 Contacting said target molecule with a catalyst capable of chemically modifying said target molecule; catalyzing the attachment of the label to the target substance
12/05/2002	US20020182194 Useful as a tumor vaccine
12/05/2002	US20020182180 Method for inducing immunity to viruses
12/05/2002	US20020182177 Methods and compositions for promoting the maturation of monocytes
12/05/2002	US20020182176 Methods and compositions for promoting the maturation of monocytes
12/05/2002	US20020182175 Administration of a reactive oxygen species (ROS) inhibitor or scavenger (a histmine or its salt, ester, prodrug and agonist) and at least one monocyte maturation promoting agent (a cytokine)
12/05/2002	US20020182174 Methods and compositions for promoting the maturation of monocytes
12/05/2002	DE10125179A1 Verwendung von LPS zur Behandlung intestinaler Entzündungsprozesse Use of LPS to treat intestinal inflammation
12/05/2002	CA2665748A1 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease
12/05/2002	CA2449127A1 Recombinant dna encoding the major allergen of plantago lanceolata pollen pla l 1, and applications thereof
12/05/2002	CA2449056A1 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
12/05/2002	CA2449026A1 Use of polyclonal immunoglobulins
12/05/2002	CA2449014A1 Method to generate non virulent microorganisms from pathogenic ones trough permanent genetic modification of their biological membrane for vaccine production
12/05/2002	CA2448956A1 Anti-ngf antibodies for the treatment of various disorders
12/05/2002	CA2448620A1 Vaccination against the feline immunodeficiency virus
12/05/2002	CA2448348A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
12/05/2002	CA2448345A1 Stable liquid formulations of antibodies
12/05/2002	CA2448171A1 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease
12/05/2002	CA2448146A1 Secreted proteins
12/05/2002	CA2448116A1 Molecules for disease detection and treatment
12/05/2002	CA2448109A1 Alternative splice forms of proteins as basis for multiple therapeutic modalities
12/05/2002	CA2448096A1 Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes
12/05/2002	CA2447879A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002	CA2447662A1 Transporters and ion channels
12/05/2002	CA2446723A1 Antibodies that immunospecifically bind to trail receptors
12/05/2002	CA2445611A1 P-cadherin as a target for anti-cancer therapy
12/05/2002	CA2443713A1 Proteins associated with cell growth, differentiation, and death
12/04/2002	EP1262554A2 Defective packaging non-oncoviral vectors based on mpmv and hiv
12/04/2002	EP1262491A2 Non-anaphylactogenic IgE vaccines
12/04/2002	EP1262193A1 Use of human anti-CTLA-4 antibodies for treatment of cancer
12/04/2002	EP1262192A2 Compositions and methods for human gastrointestinal health
12/04/2002	EP1261713A2 Human ion channels
12/04/2002	EP1261712A2 Proteins named fctrx and nucleic acids encoding same
12/04/2002	EP1261711A2 Compositions and methods for diagnosis and therapy of malignant mesothelioma
12/04/2002	EP1261708A2 Compositions and methods for the therapy and diagnosis of prostate cancer
12/04/2002	EP1261706A2 Egg specific surface proteins
12/04/2002	EP1261704A2 Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
12/04/2002	EP1261701A2 FULL-LENGTH INFECTIOUS cDNA CLONES OF TICK BORNE FLAVIVIRUS
12/04/2002	EP1261693A2 Hyperthermia and immunotherapy for leukemias, lymphomas, and solid tumors
12/04/2002	EP1261644A2 Modulation of the activity of the endothelial cell surface receptor ecrtp/dep-1 in the regulation of angiogenesis
12/04/2002	EP1261643A1 Composition for inhibiting macrophage activity
12/04/2002	EP1261640A2 Inflammation-related gene
12/04/2002	EP1261639A2 Chondromodulin-i related peptide
12/04/2002	EP1261638A2 Human fgf-23 gene and gene expression products
12/04/2002	EP1261631A1 A 52 kDa PROTEIN FROM COAGULASE NEGATIVE STAPHYLOCOCCI AND FRAGMENTS THEREOF
12/04/2002	EP1261627A2 Antibodies against plasma cells
12/04/2002	EP1261378A2 Biodegradable immunomodulatory formulations and methods for use thereof
12/04/2002	EP1261377A2 Immunomodulatory formulations and methods for use thereof
12/04/2002	EP1261376A1 Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
12/04/2002	EP1261374A2 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
12/04/2002	EP1261372A2 Method of treating cancer with anti-neurotrophin agents
12/04/2002	EP1261371A1 Membrane estrogen receptor-directed therapy in breast cancer
12/04/2002	EP1261370A1 Therapeutic method for reducing angiogenesis
12/04/2002	EP1261366A1 Adjuvant treatment by in vivo activation of dendritic cells
12/04/2002	EP1261364A1 Method of treating or inhibiting cellular injury or cell death
12/04/2002	EP1261352A2 Immunostimulatory polynucleotide sequences for use in preventing and treating respiratory viral infections
12/04/2002	EP1261320A2 Micellar pharmaceutical compositions for buccal and pulmonary application
12/04/2002	EP1261317A2 Methods and compositions for treating and preventing posterior segment ophthalmic disorders
12/04/2002	EP0938298B1 Liposome-based composition
12/04/2002	EP0824358B1 Acellular pertussis vaccines and methods of preparation thereof
12/04/2002	EP0814837B1 Use of g class immunoglobulins for the topical treatment of atopic dermatitis
12/04/2002	EP0719285B1 Il8 inhibitors
12/04/2002	EP0714441B1 Recombinant cladosporium herbarum allergens
12/04/2002	EP0693937B1 Hiv-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof

1 ... 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 ... 1823